A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
A value-based deal would boost prices should Astrazeneca's struggling heart-disease pill Brilinta outperform outcomes benchmarks.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…